PHARMACOGENETICS OF VINORELBINE IN MALIGNANT PLEURAL MESOTHELIOMA PATIENTS
N/A
N/A
N/A
N/A
N/A
Open (Enrolling)
Both
Malignant Pleural Mesothelioma Patients Treated With Vinorelbine as a Second or Later Line Chemotherapy
Both
Malignant Pleural Mesothelioma Patients Treated With Vinorelbine as a Second or Later Line Chemotherapy
Trial Information
PHARMACOGENETICS OF VINORELBINE IN MALIGNANT PLEURAL MESOTHELIOMA PATIENTS
Inclusion Criteria:
- MPM patients treated with vinorelbine in the ≥ second line setting will be
retrospectively analyzed
- Patients will be selected based on the availability of tumor tissue
Exclusion Criteria:
- NA
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Retrospective
Outcome Measure:
Expression of TUBB3 and BRCA1 in MPM tumor tissue by immunohistochemistry and RT-PCR.
Outcome Time Frame:
2 months
Safety Issue:
No
Principal Investigator
armando santoro, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Istituto Clinico Humanitas
Authority:
Italy: Ministry of Health
Study ID:
ONC/OSS-02/2012
NCT ID:
NCT01865045
Start Date:
November 2012
Completion Date:
May 2014
Related Keywords:
- Malignant Pleural Mesothelioma Patients Treated With Vinorelbine as a Second or Later Line Chemotherapy
- Mesothelioma
Name | Location |
|---|
